Breaking News, Financial News

Financial Report: InterMune

Esbriet revenues climb 188%

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

InterMune 1Q Revenues: $30.3 million (+188%) 1Q Loss: $53.6 million (loss of $49.9 million in 1Q13) Comments: Esbriet revenue in the quarter was $30.3 million, up 188%. R&D expenses were $32.1 million, up 24%, attributed to activities to complete the ASCEND Phase III trial, a higher number of patients in the RECAP extension study of pirfenidone, and activities related to the pirfenidone NDA resubmission....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters